Cellular Therapy in Oncology Market Scope
Cancer treatment has generally consisted of a mix of surgery, radiation, and chemotherapy in recent decades. Although survival rates have improved and relapse rates have reduced for most malignancies over the last several decades, the efficacy of these therapies varies significantly in response to a variety of variables. However, the scientific and medical societies have acknowledged that there is a large unmet need for more effective cancer medicines, particularly for patients with advanced malignancies who have failed to react to standard treatments. Engineered cells are a new age of targeted cancer therapy that has been viewed as a viable therapeutic possibility by experts. Engineered cell treatment (a mix of gene and cell therapy) as part of cancer targeted therapy might be a useful tool. T-Cell engineering has shown positive outcomes, whereas MSC engineering is in the early stages of development.
The Cellular Therapy in Oncology market study is segmented by Type (Consumables, Equipment (Cell Processing Equipment, Single-use Equipment) and Systems & Software) and major geographies with country level break-up.
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA estimates that United States & Germany Players will contribute to the maximum growth of Global Cellular Therapy in Oncology market throughout the predicted period.
Thermo Fisher Scientific Inc. (United States), MaxCyte (United States), Danaher Corporation (United States), Merck KGaA (Germany), Becton, Dickinson and Company (United States), Lonza Group (Switzerland), Fresenius Medical Care AG & Co. KGaA (Germany), Bio-Techne Corporation (United States), Sartorius AG (Germany) and Terumo BCT (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Avantor, Inc. (United States), RoosterBio Inc. (United States), SIRION Biotech GmbH (Germany), CellGenix GmbH (Germany), Miltenyi Biotec GmbH (Germany), STEMCELL Technologies (Canada) and IxCells Biotechnology (China).
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.
AMA Research has segmented the market of Global Cellular Therapy in Oncology market by Type, Application and Region.
On the basis of geography, the market of Cellular Therapy in Oncology has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
Market Leaders and their expansionary development strategies
On 5th February, 2021 - Bristol Myers Received FDA Approval for Cancer Cell Therapy “Breyanzi”. Breyanzi, Formerly Known as Liso-Cel, Is Used by People with Specific Kinds of Large B-Cell Lymphoma Who Have Had At Least Two Prior Therapies and Whose Disease Has Progressed. and On 5th February, 2020 - GIOSTAR (Global Institute of Stem Cell Therapy and Research) Launched Stem Cell / Cancer Research and Therapy Center in India. The Facility Is the Latest Milestone in GIOSTAR's Global Development In India, Mexico, The United States, And A Number Of Other Nations.
- Emergence of Advance Cell Therapy Procedures
- Rising R&D Investments in Cell-Based Research
- Prevalence of Cancer and Chronic Diseases
- Increasing Number of Oncology-Related Cell Therapy Clinical Trials
- Growth in Healthcare Infrastructure and Expenditure
- Low Success Rate Associated to R&D
- High-Cost Expenses
- Market Penetration Across New Regions
- Lack of Trained Professionals
Key Target AudiencePharma & Biotech Manufactures, New Entrants and Investors, Pharma & Biotech Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others
Frequently Asked Questions (FAQ):
1. Is it possible to have certain customization in the study?
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a study that suits your business objectives.
2. How big is the Cellular Therapy in Oncology Market?
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2026.